Objective: To compare patients who received preoperative intravenous (IV) plus postoperative maintenance IV tranexamic acid (TXA) therapy and perioperative periarticular TXA to those did not receive during total knee arthroplasty (TKA) in terms of blood loss, transfusion requirements, length hospital stay.
 Material Method: Data from 194 underwent TKA between 2016 2019 were reviewed. A 106...

Background: The postpartum hemorrhage is still remaining a leading cause of maternal mortality, especially in developing countries. Objective: We aimed to determine the efficacy using tranexamic acid vaginal delivery avoid and reduce blood loss hospital stay. Patients methods: A prospective-randomized clinical trial study was conducted on 92 pregnant women that were prepared for delivery. The...

Background: Perioperative blood loss is associated with total knee arthroplasty (TKA). The tranexamic acid (TXA) is a plasminogen activator inhibitor widely used to prevent bleeding. The Stryker CBC II ConstaVac Blood Conservation System (CBC II, Stryker) can avoid homologous blood. The purpose of this study is to compare the efficacy of intravenous and topical regimen of TXA in primary TKA, an...

Tranexamic acid (TXA) has been used successfully in primary total knee arthroplasty (TKA) to minimize blood loss and transfusions. The purpose of this study is to determine its efficacy in patients undergoing revision TKA. In a retrospective review of 111 patients (68 control and 43 TXA), treatment patients receiving a single intravenous TXA dose of 10mg/kg required less transfusions (P=0.03) a...

Objectives: Tranexamic acid (TXA) use has become common in Orthopedic surgeries. Despite the growing number of publications related to its use, no recent systematic reviews have been published examining TXA foot and ankle surgery. The aim this review article is provide a summary current available literature regarding surgery further understanding safety efficacy. Methods: This was following 202...

Background Perioperative tranexamic acid (TXA) use can reduce bleeding and transfusion requirements in several types of surgery, but level I evidence proving its effectiveness in major spine surgery is lacking. This study was designed to investigate the hypothesis that TXA reduces perioperative blood loss and transfusion requirements in patients undergoing major spine procedures. Methods We c...

The effectiveness of Tranexamic Acid (TXA, antifibrinolytic drug) in reducing allogeneic blood transfusion requirements has not been tested in revision total knee arthroplasty. The aim of this study was to assess the effectiveness of TXA after two intravenous doses of 1 g each. Between April 2006 and February 2010, 68 consecutive patients (19 male, 49 female) of 74 +/- 6 [m +/- SD] years of age...

Tranexamic Acid (TXA), a synthetic derivative of the amino acid lysine, was originally approved by the U.S. Food and Drug Administration in 1986 to reduce bleeding in hemophiliacs undergoing tooth extraction. It is a potent antifibrinolytic drug that both competitively inhibits the conversion of plasminogen to plasmin by saturating plasminogen’s lysine binding site [1] and by directly inhibitin...

OBJECTIVE Spinal deformity surgery has the potential risk of massive blood loss. To reduce surgical bleeding, the use of tranexamic acid (TXA) became popular in spinal surgery, recently. The purpose of this study was to determine the effectiveness of intra-operative TXA use to reduce surgical bleeding and transfusion requirements in spinal deformity surgery. METHODS A total of 132 consecutive...

Background The purpose of this study was to investigate the influence of tranexamic acid (TXA) on functional outcomes in the immediate postoperative period after total knee arthroplasty (TKA). We hypothesized that the known benefits of TXA would confer measurable clinical improvements in physical therapy (PT) performance, decrease pain, and decrease hospital length of stay (LOS). Methods We r...